Patents by Inventor Volker Laux
Volker Laux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110178039Abstract: Oligosaccharide mixtures comprising anti-Xa activities of from 190 IU/mg to 450 IU/mg and anti-IIa activities of less than 0.2 IU/mg; and having constituent oligosaccharides with an average molecular weight of from 1800 to 2400 Daltons, constituent oligosaccharides comprise from 2 to 16 saccharide units, a 4,5-unsaturated uronic acid 2-O-sulfate unit at one end, and comprising at least one ?IIa-IIs-Is hexasaccharide sequence are described. Processes for preparing the oligosaccharide mixtures, pharmaceutical compositions and articles of manufacture comprising the oligosaccharide mixtures are described. Methods of treatment and prevention comprising administering the oligosaccharide mixtures are described.Type: ApplicationFiled: March 16, 2011Publication date: July 21, 2011Applicant: AVENTIS PHARMA S.A.Inventors: Volker LAUX, Pierre MOURIER, Christian VISKOV
-
Patent number: 7956046Abstract: Oligosaccharide mixtures comprising anti-Xa activities of from 190 IU/mg to 450 IU/mg and anti-IIa activities of less than 0.2 IU/mg; and having constituent oligosaccharides with an average molecular weight of from 1800 to 2400 Daltons, constituent oligosaccharides comprise from 2 to 16 saccharide units, a 4,5-unsaturated uronic acid 2-O-sulfate unit at one end, and comprising at least one ?IIa-IIs-Is hexasaccharide sequence are described. Processes for preparing the oligosaccharide mixtures, pharmaceutical compositions and articles of manufacture comprising the oligosaccharide mixtures are described. Methods of treatment and prevention comprising administering the oligosaccharide mixtures are described.Type: GrantFiled: July 27, 2004Date of Patent: June 7, 2011Assignee: Aventis Pharma S.A.Inventors: Volker Laux, Pierre Mourier, Christian Viskov
-
Patent number: 7393840Abstract: The present invention relates to formulations based on at least one heparin, glycosaminoglycan or heparinoid and on a formulation base with a lipid component and a polymer component. The use of this formulation as drug form for oral administration of at least one heparin, glycosaminoglycan or heparinoid, and also a process for producing the formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as drug form, advantageously using melt extrusion, are described. The lipid component advantageously has active ingredient-promoting properties, while the polymer component is soluble or swellable. At least parts of the lipid component are embedded in a polymer matrix, preferably in the form of a molecular dispersion. The formulations can form emulsions in water or aqueous liquids.Type: GrantFiled: May 29, 2001Date of Patent: July 1, 2008Assignee: BASF AktiengesellschaftInventors: Jörg Rosenberg, Jörg Breitenbach, Dieter Herr, Volker Laux, Robert Heger
-
Patent number: 7365088Abstract: The present invention relates to a compound of the formula I wherein J1, J2, R0, R1, R2, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: May 19, 2004Date of Patent: April 29, 2008Assignee: Sanofi-Aventis Deutschland GmbHInventors: Marc Nazare, Volkmar Wehner, Volker Laux, Matthias Urmann, Armin Bauer, Hans Matter
-
Patent number: 7223780Abstract: The present invention is directed to the compound of formula I which is useful for inhibiting the activity of blood clotting enzyme Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically treating a patient suffering from, or subject to, a disease state associated with a cardiovascular disorder.Type: GrantFiled: May 19, 2004Date of Patent: May 29, 2007Assignee: Sanofi-Aventis Deutschland GmbHInventors: Marc Nazare, Volker Laux, Armin Bauer, Michael Wagner
-
Patent number: 7196103Abstract: The present invention is directed to the compound of formula I which is useful for inhibiting the activity of Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically or prophylactically treating a patient suffering from, or subject to, or associated with a disease state associated with a cardiovascular disorder.Type: GrantFiled: May 19, 2004Date of Patent: March 27, 2007Assignee: Sanofi-Aventis Deutschland GmbHInventors: Marc Nazare, Volkmar Wehner, Kurt Ritter, Volker Laux
-
Patent number: 7105508Abstract: The invention relates to novel compounds which bind to integrin receptors, and to the preparation thereof and the use thereof as drugs.Type: GrantFiled: August 1, 2000Date of Patent: September 12, 2006Assignee: Abbott GmbH & Co. KGInventors: Andreas Kling, Hervé Geneste, Udo Lange, Arnulf Lauterbach, Claudia Isabella Graef, Thomas Subkowski, Uta Holzenkamp, Helmut Mack, Jens Sadowski, Wilfried Hornberger, Volker Laux
-
Publication number: 20050090561Abstract: Oligosaccharide mixtures comprising anti-Xa activities of from 190 IU/mg to 450 IU/mg and anti-IIa activities of less than 0.2 IU/mg; and having constituent oligosaccharides with an average molecular weight of from 1800 to 2400 Daltons, constituent oligosaccharides comprise from 2 to 16 saccharide units, a 4,5-unsaturated uronic acid 2-O-sulfate unit at one end, and comprising at least one ?IIa-IIs-Is hexasaccharide sequence are described. Processes for preparing the oligosaccharide mixtures, pharmaceutical compositions and articles of manufacture comprising the oligosaccharide mixtures are described. Methods of treatment and prevention comprising administering the oligosaccharide mixtures are described.Type: ApplicationFiled: July 27, 2004Publication date: April 28, 2005Inventors: Volker Laux, Plerre Mourier, Christian Viskov
-
Publication number: 20050033049Abstract: The present invention is directed to the compound of formula I which is useful for inhibiting the activity of Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically or prophylactically treating a patient suffering from, or subject to, or associated with a disease state associated with a cardiovascular disorder.Type: ApplicationFiled: May 19, 2004Publication date: February 10, 2005Applicant: AVENTIS PHARMA DEUTSCHLAND GMBHInventors: Marc Nazare, Volkmar Wehner, Kurt Ritter, Volker Laux
-
Publication number: 20050009827Abstract: The present invention is directed to the compound of formula I which is useful for inhibiting the activity of Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically or prophylactically treating a patient suffering from, or subject to, or associated with a disease state associated with a cardiovascular disorder.Type: ApplicationFiled: May 19, 2004Publication date: January 13, 2005Applicant: AVENTIS PHARMA DEUTSCHLAND GMBHInventors: Marc Nazare, Volker Laux, Armin Bauer, Michael Wagner
-
Publication number: 20040235824Abstract: The present invention relates to a compound of the formula I 1Type: ApplicationFiled: May 19, 2004Publication date: November 25, 2004Applicant: Aventis Pharma Deutschland GmbHInventors: Marc Nazare, Volkmar Wehner, Volker Laux, Matthias Urmann, Armin Bauer, Hans Matter
-
Publication number: 20030161884Abstract: The present invention relates to formulations based on at least one heparin, glycosaminoglycan or heparinoid and on a formulation base with a lipid component and a polymer component. The use of this formulation as drug form for oral administration of at least one heparin, glycosaminoglycan or heparinoid, and also a process for producing the formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as drug form, advantageously using melt extrusion, are described. The lipid component advantageously has active ingredient-promoting properties, while the polymer component is soluble or swellable. At least parts of the lipid component are embedded in a polymer matrix, preferably in the form of a molecular dispersion. The formulations can form emulsions in water or aqueous liquids.Type: ApplicationFiled: November 25, 2002Publication date: August 28, 2003Inventors: Jorg Rosenberg, Jorg Breitenbach, Dieter Herr, Volker Laux, Robert Heger
-
Patent number: 6382367Abstract: An actuating piston (10) of a hydraulically and mechanically actuable, spot-type disk brake for motor vehicles, which is disposed in a sealing and displaceable manner in a cylinder bore of the disk brake is provided with an axial-force-transmitting conical surface (18) cooperating with a corresponding conical surface of a mechanical actuating device of the disk brake. To make the actuating piston (10) lighter in weight but nevertheless to withstand greater stress, the part of the actuating piston (10) comprising the axial-force-transmitting conical surface (18) consists of steel and the part of the actuating piston (10) cooperating with the cylinder bore of the disk brake is made of light metal or of plastics material, said components of the actuating piston being constructed as a single-piece composite component.Type: GrantFiled: July 25, 2000Date of Patent: May 7, 2002Assignee: Lucas Industries plcInventors: Viktor Varzescu, Roman Zimmermann, Lothar Wagner, Volker Laux
-
Patent number: 6313104Abstract: The invention relates to the use of polysulfated glycosaminoglycans having a sulfur content of at least 12.5% for producing pharmaceutical preparations for inhibiting the &ggr;-interferon-induced upregulation of the MHC Class I and MHC Class II proteins and ICAM-1. The invention furthermore relates to organoprotective solutions comprising polysulfated glycosaminoglycans and to a process for the ex-vivo protection of transplant organs.Type: GrantFiled: January 22, 1999Date of Patent: November 6, 2001Assignee: Abbott LaboratoriesInventors: F. J. van der Woude, Benito Yard, Dieter Herr, Volker Laux